Brief: Vistagen Initiates Palisade-4 Phase 3 Study Of Fasedienol For The Acute Treatment Of Social Anxiety Disorder
23/09/2024 14:37
Sept 23 (Reuters) - VistaGen Therapeutics Inc VTGN.O :
* VISTAGEN INITIATES PALISADE-4 PHASE 3 STUDY OF FASEDIENOL
FOR
THE ACUTE TREATMENT OF SOCIAL ANXIETY DISORDER
* VISTAGEN THERAPEUTICS INC: NEXT STEP IN
REGISTRATION-DIRECTED
PALISADE PHASE 3 PROGRAM FOR FASEDIENOL IN SOCIAL ANXIETY
DISORDER ACHIEVED AS PLANNED
Source text for Eikon: ID:nBw8Pr54Ma
Further company coverage: VTGN.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Vistagen Therapeutics
See all newsBrief: Vistagen TherapeuticsSays Fasedienol Nasal Spray Well-Tolerated With No New Drug-Related Safety Findings After 12 Months
VistaGen Q1 revenue rises on licensing agreement expiration
Brief: VistaGen Q1 EPS USD -0.3
Vistagen Therapeutics Inc expected to post a loss of 36 cents a share - Earnings Preview
Brief: Vistagen Appoints Douglas J. Williamson To Its Board Of Directors